Phenotypic differentiation without permanent cell-cycle arrest by skeletal myocytes with deregulated E2F-1

DNA and Cell Biology

Volumn 18, Issue 4, 1999, Pages 305-314

  Chen, Gang ^a   Lee, Eva Y H P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL TYPE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; MUSCLE CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKELETAL MUSCLE;

ANIMALIA;

EID: 0032932364     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454999315367     Document Type: Article

References (70)

1. ACKLAND-BERGLUND, C.E., and LEIB, D.A. (1995). Efficacy of tetracycline-controlled gene expression is influenced by cell type. Biotechniques 18, 196-200.
2. ALMASAN, A., YIN, Y., KELLY, R.E., LEE, E., Y.-H.P., BRADLEY, A., LI, W., BERTINO, J.R., and WAHL, G.M. (1995). Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F responsive genes, and apoptosis. Proc. Natl. Acad. Sci. USA 92, 5436-5440.
3. ANDRES, V., and WALSH, K. (1996). Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J. Cell Biol. 132, 657-665.
4. BAGCHI, S., WEINMANN, R., and RAYCHAUDHURI, P. (1991). The retinoblastoma protein co-purifies with E2F-1, an E1A-regulated inhibitor of transcription factor E2F. Cell 65, 1063-1072.
5. BEIJERBERGEN, R.L., KERKHOVEN. R.M., ZHU, L., CARLEE. L., VOORHOEVE, P.M., and BERNARDS, R. (1994). E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev. 8, 2680-2690.
6. BERNARDS, R. (1997). E2F: a nodal point in cell cycle regulation. Biochim. Biophys. Acta 1333, M33-M40.
7. BRADFORD, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
8. BREHM, A., MISKA. E.A., McCANCE, D.J., REID, J.L. BANNISTER, A.J., and KOUZARIDES, T. (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391, 597-601.
9. CHELLAPPAN, S.P., HIEBERT, S., MUDRYJ, M., HOROWITZ, J.M., and NEVINS, J.R. (1991). The E2F transcription factor is a cellular target for the RB protein. Cell 65, 1053-1061.
10. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
11. CLEGG, C.H., LINKART, T.A., OLWIN, B.B., and HAUSCHKA, S.D. (1987). Growth factor control of skeletal muscle differentiation occurs in G1 phase and is repressed by fibroblast growth factor. J. Cell Biol. 105, 949-956.
12. CLEGG, C.H., and HAUSCHKA, S.D. (1987). Heterokaryon analysis of muscle differentiation, regulation of the post-mitotic state. J. Cell Biol. 105, 937-947.
13. CRESCENZI, M., SODDU, S., and TATO, F. (1995). Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. J. Cell. Physiol. 162, 26-35.
14. DEGREGORI. J., LEONE, G., OHTANI, K., MIRON, A., and NEVINS, J.R. (1995). E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9, 2873-2887.
15. DURONIO, R.J., O'FARRELL, P.H., XIE, J.-E., BROOK, A., and DYSON, N. (1995). The transcription factor E2F is required for S phase during Drosophila embryogenesis. Genes Dev. 9, 1445-1455.
16. DYNLACHT, B.D., FLORES, O., LEES, J.A., and HARLOW, E. (1994). Differential activation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 8, 1772-1786.
17. DYSON, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262.
18. ELLEDGE, S.J., and HARPER, J.W. (1994). Cdk inhibitors, on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6, 847-852.
19. ENDO, T., and GOTO, S. (1992). Retinoblastoma gene product Rb accumulates during myogenic differentiation and is deinduced by the expression of SV40 large T antigen. J. Biochem. 112, 427-430.
20. ENDO, T., and NADAL-GINARD, B. (1989). SV40 large T-antigen induces reentry of terminally differentiated myotubes into the cell cycle. In The Cellular and Molecular Biology of Muscle Development. L.H. Kedes and F.E. Stockdale, eds. (Alan R. Liss, New York) pp. 95-104.
21. FLORINI, J.R., and MARGI, K.A. (1989). Effects of growth factors on myogenic differentiation. Am. J. Physiol. 256, C701-C711.
22. GINSBERG, D., VAIRO, G., CHITTENDDEN, T., XIAO, Z.-X., XU, G., WYDNER, K.L., DECAPRIO, J.A., LAWRENCE, J.B., and LIVINGSTON, D.M. (1994). E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev. 8, 2665-2679.
23. GIRLING, R., PARTRIDGE, J.F., BANDARA, L.R., BURDEN, N., TOTTY, N.F., HSUAN. J.J., and LA THANGUE, N.B. (1993). A new component of the transcriptional factor DRTF1/E2F. Nature 362, 83-87.
24. GOSSEN, M., and BUJARD, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551.
25. GU, W., SCHNEIDER, J.W., CONDORELLI, G., KAUSHAL, S., MAHDAVI, V., and NADAL-GINARD, B. (1993). Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72, 309-324.
26. HALEVY, O., NOVITCH, B.G., SPICER, D.B., SKAPEK, S.X., RHEE, J., HANNON, G.J., BEACH, D., and LASSAR, A.B. (1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267, 1018-1021.
27. HELIN, K., LEES, J.A., VIDAL, M., DYSON, N., HARLOW, E., and FATTAEY, A. (1992). A cDNA encoding a RB-binding protein with properties of the transcription factor E2F. Cell 70, 337-350.
28. HELIN, K., WU, C.L., FATTAEY, A.R., LEES, J.A., DYNLACHT, B.D., NGWU, C., and HARLOW, E. (1993a). Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev. 7, 1850-1861.
29. HELIN, K., HARLOW, E., and FATTAEY, A. (1993b). Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol. 13, 6501-6508.
30. IVEY-HOYLE, M., CONROY, R., HUBER, H., GOODHART, P., OLIFF, A., and HEINBROOK, D.C. (1993). Cloning and characterization of E2F-2, a novel protein with biochemical properties of the transcription factor E2F. Mol. Cell. Biol. 13, 7802-7812.
31. JOHNSON, D.G., SCHWARZ, J.K., CRESS, W.D., and NEVINS, J.R. (1993). Expression of E2F1 induces quiescent cells to enter S phase. Nature 365, 349-352.
32. KAELIN, W.G., KREK, W., SELLERS, W.R., DECAPRIO, J.A., AJCHENBAUM, F., FUCHS, C.S., CHITTENDEN, T., LI, Y., FARNHAM, P.J., BLANAR, M.A., LIVINGSTON, D.M., and FLEMINGTON, E.K. (1992). Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell 70, 351-364.
33. LA THANGUE, N.B. (1994). DP and E2F proteins, components of a heterodimeric transcription factor implicated in cell cycle control. Curr. Opin. Cell Biol. 6, 443-450.
34. LASSAR, A.B., SKAPEK. S.X., and NOVITCH, B. (1994). Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr. Opin. Cell Biol. 6, 788-794.
35. LEES, J.A., SAITO, M., VIDAL, M., VALENTINE, M., LOOK, T., HARLOW, E., DYSON, N., and HELIN, K. (1993). The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell. Biol. 13, 7813-7825.
36. LUO, R.X., POSTIGO, A.A., and DEAN, D.C. (1998). Rb interacts with histone deacetylase to repress transcription. Cell 92, 463-473.
37. MACLEOD, K.F., HU, Y., and JACKS, T. (1996). Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 15, 6178-6188.
38. MAGNAGHI-JAULIN, L., GROISMAN, R., NAGUIBNEVA, I., ROBIN, P., LARAIN, S., LE VILLAIN, J.P., TROALEN, F., TROUCHE, D., and HAREL-BELLAN, A. (1998). Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391, 601-604.
39. MARTELLI, F., CENCIARELLI, C., SANTARELLI, G., POLIKAR, B., FELSANI, A., and CARUSO, M. (1994). MyoD induces retinoblastoma gene expression during myogenic differentiation. Oncogene 9, 3579-3590.
40. MINSHULL, J., GOLSTEYN, R., HILL, C.S., and HUNT, T. (1990). The A- and B-type cyclin associated cdc2 kinases in Xenopus turn on and off at different times in the cell cycle. EMBO J. 9, 2865-2875.
41. NADAL-GINARD, B. (1978). Commitment, fusion and biochemical differentiation of a myogenic cell line in the absence of DNA synthesis. Cell 15, 855-864.
42. NEVINS, J.R., LEONE, G., DEGREGORI, J., and JAKIO, L. (1997). Role of the Rb/E2F pathway in cell growth control. J. Cell. Physiol. 173, 233-236.
43. 2 phases of the cell cycle. J. Cell Biol. 135, 441-456.
44. OLSON, E.N. (1992). Interplay between proliferation and differentiation within the myogenic lineage. Dev. Biol. 154, 261-272.
45. OLSON, E.N., PERRY, M., and SCHULZ, R.A. (1995). Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Dev. Biol. 172, 2-14.
46. cip1 in muscle and other terminally differentiating cells. Science 267, 1024-1027.
47. PINES, J., and HUNTER, T. (1991). Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J. Cell Biol. 115, 1-17.
48. PURI, P.L., BALSANO, C., BURGIO, V.L., CHIRILLO, P., NATOLI, G., RICCI, L., MATTEI E., GRAESSMANN, A., and LEVRERO, M. (1997). MyoD prevents cyclin A/cdk2 containing E2F complexes formation in terminally differentiated myocytes. Oncogene 14,1171-1184.
49. QIAN, Y.W., WANG, Y.C., HOLLINGSWORTH, R.E., JR, JONES, D., LING, N., and LEE, E.Y. (1993). A retinoblastoma-binding protein related to a negative regulator of Ras in yeast. Nature 364, 648-652.
50. QIN, X.Q., LIVINGSTON, D.M., KAELIN, W.G., and ADAMS, P.D. (1994). Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91, 10918-10922.
51. RILEY, D.J., LEE, E.Y.-H.P., and LEE, W.-H. (1994). Retinoblastoma gene, more than a tumor suppressor. Annu. Rev. Cell. Biol. 10, 1-29.
52. SAMBROOK, J., FRITSCH, E.F., and MANIATIS. T. (1989). Molecular Cloning: A Laboratory Manual, ed. 2. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
53. -/- muscle cells. Science 264, 1467-1471.
54. SELLERS, W.R., BOVITCH, B.G., MIYAKE, S., HEITH, A., OTTERSON, G.A., KAYE, F.J., LASSAR, A.B., and KAELIN, W.G. (1998). Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor growth. Genes Dev. 12, 95-106.
55. SHAN, B., ZHU, X., CHEN, P.-L., DURFEE, T., YANG, Y., SHARP, D., and LEE, W.-H. (1992). Molecular cloning of cellular genes encoding retinoblastoma-associated proteins, identification of a gene with properties of the transcription factor E2F. Mol. Cell. Biol. 12, 5620-5631.
56. SHAN, B., and LEE, W.-H. (1994). Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14, 8166-8173.
57. SHERR, C.J. (1994). G1 phase progression: cyclin on cue. Cell 79, 551-555.
58. SHERR, C.J., and ROBERTS. J.M. (1995). Inhibition of G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
59. SHIN, E.K., SHIN, A., PAULDING, C., SCHAFFHAUSEN, B., and YEE, A.S. (1995). Multiple changes in E2F function and regulation occur upon muscle differentiation. Mol. Cell. Biol. 15, 2252-2262.
60. STOCKDALE, F.E., and HOLTZER, H. (1961). DNA synthesis and myogenesis. Exp. Cell Res. 24, 508-520.
61. TIAINEN, M., PAJALUNGA, D., FERRANTELLI, F., SODDU, S., SALVATORI, G., SACCHI, A., and CRESCENZI, M. (1996). Terminally differentiated skeletal myotubes are not confined to G0 but can enter G1 upon growth factor stimulation. Cell Growth Differ. 7, 1039-1050.
62. TRIMARCHI, J.M., FAIRCHILD, B., VERONA, R., MOBERG, K., ANDON, N., and LEES, J.A. (1998). E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc. Natl. Acad. Sci. USA 95, 2850-2855.
63. TSAI, K.Y., HU, Y., MACLEOD, K.F., CROWLEY, D., YAMASAKI, L., and JACKS, T. (1998). Mutation of E2F-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell 2, 293-304.
64. VAIRO, G., LIVINGSTON, D.M., and GINSBERG, D. (1995). Functional interaction between E2F-4 and p 130, evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev. 9, 869-881.
65. WANG, J., HELIN. K., JIN, P., and NADAL-GINARD, B. (1995). Inhibition of in vitro myogenic differentiation by cellular transcription factor E2F1. Cell Growth Differ. 6, 1299-1306.
66. WEINBERG, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
67. WEINTRAUB, H., DAVIS, R., TAPSCOTT, S., THAYER, M., KRAUSE, M., BENEZRA, B., BLACKWELL, T.K., TURNER. D., RUPP, R., HOLLENBERG, S., ZHUANG, Y., and LASSER, A. (1991). The MyoD gene family, nodal point during specification of the muscle cell lineage. Science 251, 761-766.
68. WU, X., and LEVINE, A.J. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91, 3602-3606.
69. YAMASAKI, L., BRONSON, R., WILLIAMS, B.O., DYSON, N.J., HARLOW, E., and JACKS, T. (1998). Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nature Genet. 18, 360-364.
70. ZACKSENHAUS, E., JIANG, Z., CHUNG, D., MARTH, J.D., PHILLIPS, R.A., and GALLIE, B.L. (1996). pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev. 10, 3051-3064.